Betrixaban

Betrixaban

Clinical data
ATC code	none
Identifiers
IUPAC name N-(5-chloropyridin-2-yl)-2-([4-(N,N-dimethylcarbamimidoyl)benzoyl]amino)-5-methoxybenzamide
CAS Number	330942-05-7 N
PubChem CID	10275777
ChemSpider	18981107 Y
UNII	74RWP7W0J9
ChEMBL	ChEMBL512351 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H22ClN5O3
Molar mass	451.905 g/mol
3D model (JSmol)	Interactive image
SMILES CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
InChI InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31) Y Key:XHOLNRLADUSQLD-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Betrixaban
Articles
Most recent articles on Betrixaban Most cited articles on Betrixaban Review articles on Betrixaban Articles on Betrixaban in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Betrixaban Images of Betrixaban Photos of Betrixaban Podcasts & MP3s on Betrixaban Videos on Betrixaban
Evidence Based Medicine
Cochrane Collaboration on Betrixaban Bandolier on Betrixaban TRIP on Betrixaban
Clinical Trials
Ongoing Trials on Betrixaban at Clinical Trials.gov Trial results on Betrixaban Clinical Trials on Betrixaban at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Betrixaban NICE Guidance on Betrixaban NHS PRODIGY Guidance FDA on Betrixaban CDC on Betrixaban
Books
Books on Betrixaban
News
Betrixaban in the news Be alerted to news on Betrixaban News trends on Betrixaban
Commentary
Blogs on Betrixaban
Definitions
Definitions of Betrixaban
Patient Resources / Community
Patient resources on Betrixaban Discussion groups on Betrixaban Patient Handouts on Betrixaban Directions to Hospitals Treating Betrixaban Risk calculators and risk factors for Betrixaban
Healthcare Provider Resources
Symptoms of Betrixaban Causes & Risk Factors for Betrixaban Diagnostic studies for Betrixaban Treatment of Betrixaban
Continuing Medical Education (CME)
CME Programs on Betrixaban
International
Betrixaban en Espanol Betrixaban en Francais
Business
Betrixaban in the Marketplace Patents on Betrixaban
Experimental / Informatics
List of terms related to Betrixaban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Betrixaban (INN, codenamed PRT-054,021) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity. Betrixaban has undergone human phase 1 and 2 clinical trials for prevention of pulmonary embolism after knee surgery, and prevention of stroke following atrial fibrillation,.

Chemical Properties

Betrixaban is a potent and specific inhibitor of human factor Xa (fXa) activity which acts by binding to the active site of fXa. Betrixaban as the maleate salt has a molecular weight (MW) of 567.98

Pharmacokinetics

Betrixaban is available for oral administration as an immediate release capsule. It is rapidly absorbed with mean peak concentrations occurring 3-4 hours after oral administration. Oral bioavailability of an 80 mg dose is approximately 34% and protein binding is approximately 60%. The drug exhibits nonlinear kinetics within the expected therapeutic dosing range with greater than proportional increases in plasma concentrations occurring with increased dose; maximum plasma concentration (Cmax) and area under the curve (AUC) at steady-state increased approximately 3-fold when the dose was doubled from 40 mg to 80 mg. Excretion is mostly unchanged through the bile with renal clearance approximately 7-10% of the absorbed dose. When administered after a high-fat, high-calorie breakfast, Cmax and AUC were reduced by approximately 50% as compared to the fasting state. Betrixaban is not a substrate for major cytochrome P450 enzymes. It is a substrate for efflux proteins including permeability glycoprotein (P-glycoprotein or P-gp). When co-administered with the potent P-gp inhibitor, ketoconazole, betrixaban concentrations were increased approximately 2-fold. Based on population pharmacokinetic (PK) analysis from the Phase II EXPLORE Xa study, a similar effect was observed when betrixaban was given concomitantly with amiodarone. A drug interaction study with the P-gp substrate, digoxin, showed no significant interaction, and one with the inhibitor verapamil suggests that co-administration in fasted state increases both Cmax and exposure to betrixaban.

Phase 1 and 2 Studies

To date betrixaban has been studied in 22 Phase I and II studies performed in 1,411 normal healthy volunteers and patients (1,200 of whom received betrixaban). Of these, nineteen Phase I studies were conducted in 499 normal healthy volunteers (459 received betrixaban) and three Phase II studies were conducted in 697 patients with atrial fibrillation (AF) (570 received betrixaban and 127 received comparator drug) and in 215 post-surgical patients after knee replacement (171 received betrixaban and 43 received comparator drug, 1 patient did not receive study drug). In Phase I studies enrolling healthy subjects, single doses between 5 and 550 mg were well tolerated, as were 10-day regimens of 40, 80 and 120 mg every 12 hours (H). In the EXPERT study , betrixaban doses of 15 and 40 mg twice daily (BID) showed activity in the prevention of VTE after total knee replacement (TKR) when compared to historical control and a small concurrent enoxaparin control group. Major and minor bleeding rates were low and comparable between the betrixaban and enoxaparin treated groups. The results of the EXPERT study indicate that prophylaxis with betrixaban appeared comparable to optimal use of enoxaparin. Results of the EXPLORE Xa study (,) demonstrate that once daily doses of 40, 60 and 80 mg for stroke prevention in patients with non-valvular AF were well tolerated with all doses of betrixaban having a favorable bleeding profile compared to warfarin. Very low rates of stroke in all treatment groups that were observed in this study suggests active anticoagulant effect.